FDA-NDA202293
Document details
Summary
New FDA approval: FARXIGA (DAPAGLIFLOZIN) by AstraZeneca Pharmaceuticals LP. Oral — likely Part D.FARXIGA (DAPAGLIFLOZIN) approved 2014-01-08
Affected specialty
Multi-specialty alerts →Source document
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s000lbl.pdfCLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FR-2026-13572 · Multi-specialty
CMS is establishing a new data matching program with the Department of Veterans Affairs (VA) to verify eligibility for insurance affordability programs under the ACA. This is an administrative Privacy
View alertPolicy FR-2026-13602 · Multi-specialty
CMS proposes CY 2027 Home Health PPS rate updates including recalibrated case-mix weights, updated functional impairment levels, comorbidity subgroups, and LUPA thresholds. The rule also proposes a te
View alertPolicy FR-2026-13603 · Multi-specialty
CMS is publishing a Paperwork Reduction Act notice seeking public comment on a proposed information collection activity. This is an administrative notice with no direct changes to billing codes, reimb
View alertPolicy FR-2026-13464 · Multi-specialty
CMS is publishing a Paperwork Reduction Act notice seeking public comment on a proposed information collection activity. This is an administrative notice with no direct changes to Medicare billing, re
View alert